Brivaracetam (3) (Briviact®) – Focal seizures in epilepsy, additional therapy, 2 to < 4 years


Start date 01.03.2022
Resolution 01.09.2022
INN Brivaracetam
Brand name Briviact®
Pharm. company UCB Pharma GmbH
G-BA procedure ID 2022-03-01-D-791
Therapeutic area Nervous system diseases
Reason for procedure New Indication

G-BA resolution "Anwendungsgebiet des Beschlusses" (German)

Adjunctive treatment of focal seizures with or without secondary generalization in children 2 to < 4 years of age with epilepsy.

Subpopulation Indication Comparator
Children aged 2 to < 4 years with focal epileptic seizures with or without secondary generalisation in adjunctive therapy A patient-individual additional antiepileptic therapy, as far as medically indicated and if in each case no pharmacoresistance (in the sense of an insufficient response), intolerance or contraindication is known, taking into account the basic and (previous) therapy(s) and taking into account the reason for the change in therapy as well as any accompanying side effects

9. Associated procedures

<< List of all resolutions